With Phase III Failure, Exelixis Drops First-Line Liver Cancer Plans For Cabometyx

 
• By Joseph Haas
  
Exelixis needs new strategy
Exelixis needs a new strategy in first-line liver cancer after Phase III miss • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D